Petosemtamab Posts 28.2-Month Survival in Head and Neck Cancer, 75% Response in Colorectal
GMAB sits 88% above its 52-week low of $23.62.
Summary
Genmab presented updated petosemtamab data at ESMO across two tumor types. In first-line head and neck squamous cell carcinoma, petosemtamab plus pembrolizumab produced a median overall survival of 28.2 months, a 63% response rate and 19% complete responses, with no Grade 5 adverse events; the global Phase 3 readout is expected later this year. In metastatic colorectal cancer, the drug combined with chemo delivered objective response rates of 75% first-line and 67% second-line, rising to 81% in left-sided first-line tumors, with disease control of 95% and 93%. Genmab also struck a clinical trial collaboration with Incyte to test petosemtamab with Incyte's KRAS G12D candidate INCB161734 in first-line KRAS G12D colorectal cancer, with Incyte co-funding the Phase 1/2 study. The stock rose 1.56% to $44.93, a new 52-week high, adding to the October 23 RAINFOL-02 Phase 3 win for Rina-S. The Phase 3 head and neck topline later this year is the next binary event.
At the time of this announcement, GMAB was trading at $44.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.6B. The 52-week trading range was $23.62 to $45.45. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.